New drug for rheumatoid arthritis to be launched
Certolizumab pegol (Cimzia), a pegylated antitumour necrosis factordrug for the treatment of moderate to severe active rheumatoidarthritis, will be available in the UK from 23 October 2009
Certolizumab pegol (Cimzia), a pegylated antitumour necrosis factor drug for the treatment of moderate to severe active rheumatoid arthritis, will be available in the UK from 23 October 2009.
Certolizumab pegol, given as a subcutaneous injection in combination with methotrexate, is indicated for adult patients inadequately responsive to disease-modifying antirheumatic drugs. It can also be given as monotherapy in patients unsuitable for methotrexate therapy.
According to UCB Pharma, the manufacturer of the drug, certolizumab pegol has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.
Certolizumab pegol is a tumour necrosis factor alpha (TNFa) inhibitor. TNFa is a pro-inflammatory cytokine with a central role in inflammatory processes.
Citation: The Pharmaceutical Journal URI: 10982005
Recommended from Pharmaceutical Press